Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
US5849695A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jan 13, 1993 |
| Grant date | Dec 15, 1998 |
| Priority date | — |
| Expiry date | Jan 13, 2013 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/29
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates polypeptide analogs which have agonist or antagonist or tissue selection properties relative to parathyroid hormone (PTH), parathyroid hormone-like protein (PLP) or parathyroid-related protein (PTHrP). The serine amino acid at position 3, the glutamine amino acid at position 6, the histidine amino acid at position 9 or combinations thereof are substituted by other natural or synthetic amino acids. Preferably, a human PTH fragment of about 34 amino acids is sufficient for pharmacological activity. These polypeptides are useful as agonists or antagonists in the treatment of a human being for disease conditions of cancer, osteoporosis, hypercalcemia, or hyperparathyroid disease conditions. The invention also concerns a method of performing certain assays using the modified peptides, and based on the results of the assays falling within preset limits, selecting those modified peptides which shall be useful in the treatment of disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.